Head and neck diseases

Summary

The Head and neck research group, as part of its line of cancer research, studies new therapeutic targets and predictive biomarkers of response to chemotherapy, radiotherapy and immunotherapy, the role of the human papilloma virus (HPV) and the differential management of HPV+ tumours, transoral treatment of laryngeal cancer with CO2 laser and robotic surgery, reconstructive surgery and pharyngeal rehabilitation of laryngectomised patients

406 Publications

Strategic lines

Recurrent respiratory papillomatosis. etiologic, clinic and treatment aspects, vaccine effects on the evolution and control of this desease.
The new era of ear surgery : endoscopic ear surgery, safe techniques and results.
Impacts of body composition in head and neck cancer
New techniques for the surgical management of hereditary hemorragic telangiectasia (rendu-osler-weber disease)
The effects of biologic treatments in chronic rhinosinusitis with polyposis.
Radiomics and head and neck tumors
The implementation of artificial intelligence in the diagnosis and management of head and neck tumors
CT evaluation of sinonasal anatomy to improve the results and safeness of functional endoscopic sinonasal surgery
Robotic surgery implementation and results in head and nceck cancer
HPV and head and neck cancer

Selected Publications

Spreaflco,A;Heirali,AA;Araujo,DV;Tan,TJ;Oliva,M;Schneeberger,PHH;Chen,B et al, First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial), Ann. Oncol., 2023;34(6):520-530, doi:10.1016/j.annonc.2023.02.011
Mosteiro,M;Azuara,D;Villatoro,S;Alay,A;Gausachs,M;Varela,M;Baixeras,N et al, Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre, ESMO Open, 2023;8(6):doi:10.1016/j.esmoop.2023.102197
Hijazo Pechero,S;Alay,A;Cordero,D;Marin,R;Vilariño,N;Palmero,R;Brenes,J et al, Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications, Mol. Oncol., 2023;18(2):453-470, doi:10.1002/1878-0261.13550
Naval Baudin,P;Pons Escoda,A;Camins,À;Arroyo,P;Viveros,M;Castell,J;Cos,M et al, Deeply 3D-T1-TFE hypointense voxels are characteristic of phase-rim lesions in multiple sclerosis., Eur. Radiol., 2023;34(2):1337-1345, doi:10.1007/s00330-023-09784-w
Majós,C;Pons Escoda,A;Naval,P;Guell,A;Lucas,A;Vidal,N;Cos,M et al, Proton MR spectroscopy shows improved performance to segregate high-grade astrocytoma subgroups when defined with the new 2021 World Health Organization classification of central nervous system tumors, Eur. Radiol., 2023;doi:10.1007/s00330-023-10138-9

Selected Projects

19ACL261. ESTUDIO CLÍNICO DE FASE 3, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE PEMBROLIZUMAB (MK-3475) CON O SIN LENVATINIB (E7080/MK-7902) PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE PEMBROLIZUMAB Y LENVATINIB COMO INTERVENCIÓN DE PRIMERA LÍNEA EN UNA P. MERCK SHARP & DOHME ESPAÑA S.A.. Budget: 313.548€. 2019- . PI: OLIVA BERNAL, MARC.
20ACL093. A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. GlaxoSmithKline Research & Development Limited;GlaxoSmithKline, S.A. Budget: 236.335,84€. 2020- . PI: Plana Serrahima, María.
2023-491-1. PHASE 1-2 STUDY INVESTIGATING SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF ANTI-TIM-3 MONOCLONAL ANTIBODY BGB-A425 IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY TISLELIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS. BEIGENE SWITZERLAND GMBH. Budget: 233.370€. 2023- . PI: OLIVA BERNAL, MARC.
20ACL112. Estudio clínico de fase 2, aleatorizado, abierto y de tres grupos para evaluar la seguridad y la eficacia de lenvatinib (E7080/MK-7902) en combinación con pembrolizumab (MK-3475) frente a la quimioterapia de referencia y lenvatinib en monoterapia en parti. MERCK SHARP & DOHME ESPAÑA S.A.. Budget: 215.055€. 2020- . PI: Taberna Sanz, Miren.
2023-351-1. ENSAYO DE FASE I, ABIERTO, DE ESCALADO DE DOSIS DE BI 1831169 EN MONOTERAPIA Y EN COMBINACIÓN CON EZABENLIMAB EN PACIENTES CON TUMORES SÓLIDOS AVANZADOS O METASTÁSICOS. Boehringer Ingelheim España, S.A.. Budget: 201.126€. 2023- . PI: OLIVA BERNAL, MARC.